|
Feb 18
|
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
|
|
Feb 14
|
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
|
|
Feb 13
|
Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders
|
|
Feb 11
|
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
|
|
Feb 10
|
Regeneron’s macular oedema therapy shows promise in Phase III trial
|
|
Feb 10
|
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
|
|
Jan 24
|
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?
|
|
Jan 23
|
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
|
|
Jan 21
|
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
|
|
Jan 19
|
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
|
|
Jan 7
|
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
|
|
Jan 6
|
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder
|
|
Jan 2
|
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
|
|
Jan 1
|
Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future
|
|
Dec 31
|
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years
|
|
Dec 23
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Dec 19
|
Regeneron says study data support big bet on new blood thinners
|
|
Dec 19
|
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
|
|
Dec 18
|
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
|
|
Dec 18
|
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
|